Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis

• Status: Enrolling by invitation
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Milton S. Hershey Medical Center
• Treatments: Oxymetazoline; Phenylephrine

Criteria

Inclusion Criteria:

1. Over 18 years of age

2. Primary diagnosis of nonflaccid facial paralysis (aberrant regeneration syndrome) and acquired blepharoptosis.

Exclusion Criteria:

1. Patients under the age of 18

2. Patients on cardiac glycosides

3. Patients on MAO inhibitors

4. Patients with angle closure glaucoma

5. Patients who experience asymmetrical eye opening due to weakness (e.g. lagophthalmos).